GUIDELINES IN DERMATOLOGY

gdkapak

ATOPIC DERMATITIS

Murat Borlu1
Eda Öksüm Solak2

1Erciyes University, Faculty of Medicine, Department of Dermatology and Venereology, Kayseri, Türkiye
2Erciyes University, Faculty of Medicine, Department of Dermatology and Venereology, Kayseri, Türkiye

Borlu M, Öksüm Solak E. Atopic Dermatitis. In: Kutlubay Z, editor. Guidelines in Dermatology. 1st ed. Ankara: Türkiye Klinikleri; 2025. p.23-35.

ABSTRACT

Atopic dermatitis (AD) is a chronic, pruritic, recurrent, systemic, inflammatory skin disease often associated with other atopic conditions such as allergic asthma, allergic rhinitis, and food allergies. While AD can manifest at any age, it is most commonly observed in children and is considered part of the “atopic march,” wherein affected children have an increased risk of developing allergic conditions like asthma and allergic rhinitis later in life. Typically, AD onset occurs in infancy, usually between 3-6 months. Although many patients experience remission during adolescence, a subset, ranging from 10-30%, may not recover. Additionally, a minority of patients may first present with symptoms in adulthood. Recent research indicates that AD prevalence in adults may be higher than previously recognized, with a 1-year US prevalence ranging from 3-10%. Moreover, the incidence of AD has significantly increased in industrialized nations over the last three decades. This article discusses the pathogenesis, diagnosis, and treatment of atopic dermatitis, aiming to provide insights based on current literature.

Keywords: Dermatitis, atopic; Biological therapy; Janus kinase inhibitors; Dupilumab; Administration, Topical; Skin Care

Referanslar

  1. Lugović-Mihić L, Meštrović-Štefekov J, Potočnjak I, Cindrić T, Ilić I, Lovrić I, Skalicki L, Bešlić I, Pondeljak N. Atopic Dermatitis: Disease Features, Therapeutic Options, and a Multidisciplinary Approach. Life. 2023;13(6):1419. [Crossref]  [PubMed]  [PMC]
  2. Weidinger S, Beck LA, Bieber T, Kabashima K, Irvine AD. Atopic dermatitis. Nat Rev Dis Primers. 2018;4(1):1. [Crossref]  [PubMed]
  3. Ertam İ, Su Ö, Alper S, Sarıcaoğlu H, Karadağ AS, Odyakmaz Demirsoy E, et al. The Turkish guideline for the diagnosis and management of atopic dermatitis. Turkderm-Turk Arch dermatol venereology. 2018;52:6-23. [Crossref]
  4. Flohr C, England K, Radulovic S, McLean WH, Campbel LE, Barker J, et al. Filaggrin loss-of-function mutations are associated with early-onset eczema, eczema severity and transepidermal water loss at 3 months of age. Br J Dermatol. 2010;163(6):1333-6. [Crossref]  [PubMed]
  5. Jungersted JM, Scheer H, Mempel M, Baurecht H, Cifuentes L, Høgh JK, et al. Stratum corneum lipids, skin barrier function and filaggrin mutations in patients with atopic eczema. Allergy. 2010;65(7):911-8. [Crossref]  [PubMed]
  6. Esaki H, Brunner PM, Renert-Yuval Y, Czarnowicki T, Huynh T, Tran G, et al. Early-onset pediatric atopic dermatitis is TH2 but also TH17 polarized in skin. J Allergy Clin Immunol. 2016;138(6):1639-1651. [Crossref]  [PubMed]
  7. Kellogg C, Smogorzewski J. Update on Atopic Dermatitis. Adv Pediatr. 2023;70(1):157-170. [Crossref]  [PubMed]
  8. Renert-Yuval Y, Thyssen JP, Bissonnette R, Bieber T, Kabashima K, Hijnen D, et al. Biomarkers in atopic dermatitis-a review on behalf of the International Eczema Council. J Allergy Clin Immunol. 2021;147(4):1174-1190.e1. [Crossref]  [PubMed]  [PMC]
  9. Leung DY, Guttman-Yassky E. Deciphering the complexities of atopic dermatitis: shifting paradigms in treatment approaches. J Allergy Clin Immunol. 2014;134(4):769-79. [Crossref]  [PubMed]  [PMC]
  10. Totté JE, van der Feltz WT, Hennekam M, van Belkum A, van Zuuren EJ, Pasmans SG. Prevalence and odds of Staphylococcus aureus carriage in atopic dermatitis: a systematic review and meta-analysis. Br J Dermatol. 2016;175(4):687-95. [Crossref]  [PubMed]
  11. Paller AS, Kong HH, Seed P, Naik S, Scharschmidt TC, Gallo RL, et al. The microbiome in patients with atopic dermatitis. J Allergy Clin Immunol. 2019;143(1):26-35. [Crossref]  [PubMed]  [PMC]
  12. Katoh N, Ohya Y, Ikeda M, Ebihara T, Katayama I, Saeki H, et al; Committee for Clinical Practice Guidelines for the Management of Atopic Dermatitis 2018, The Japanese Society of Allergology, The Japanese Dermatology Association. Japanese guidelines for atopic dermatitis 2020. Allergol Int. 2020;69(3):356-369. [Crossref]  [PubMed]
  13. Rudikoff D, Lebwohl M. Atopic dermatitis. Lancet. 1998;351(9117):1715-21. [Crossref]  [PubMed]
  14. Borlu M, Öksüm Solak E. Erişkin başlangıçlı atopik dermatitte tanı ve hastalık yönetimi. Su Küçük Ö, editör. Atopik dermatit. 1. baskı. Ankara: Türkiye Klinikleri; 2020. p.71-4. [Link]
  15. Julián-Gónzalez RE, Orozco-Covarrubias L, Durán-McKinster C, Palacios-Lopez C, Ruiz-Maldonado R, Sáez-de-Ocariz M. Less common clinical manifestations of atopic dermatitis: prevalence by age. Pediatr Dermatol. 2012;29(5):580-3. [Crossref]  [PubMed]
  16. Hanifn J, Rajka G. Diagnostic features of atopic eczema. Acta Dermato Venereol. 1980;92:44-7. [Crossref]
  17. Hanifin JM, Cooper KD, Ho V, Kang S, Krafchik BR, Margolis DJ, et al. Guidelines of care for atopic dermatitis, developed in accordance with the American Academy of Dermatology (AAD)/American Academy of Dermatology Association "Administrative Regulations for Evidence-Based Clinical Practice Guidelines" J. Am. Acad. Dermatol. 2004;50:391-404. [Crossref]  [PubMed]
  18. Rehal B, Armstrong AW. Health outcome measures in atopic dermatitis: a systematic review of trends in disease severity and quality-of-life instruments 1985-2010. PLoS One. 2011;6(4):e17520. [Crossref]  [PubMed]  [PMC]
  19. Eichenfield LF. consensus guidelines in diagnosis and treatment of atopic dermatitis. Allergy. 2004;78(59 Suppl):86-92. [Crossref]  [PubMed]
  20. Schmitt J, langan S, Williams Hc. European dermato-Epidemiology Network: What are the best outcome measurements for atopic eczema? A systematic review. J Allergy clin Immunol. 2007;120:1389-98. [Crossref]  [PubMed]
  21. Eichenfield LF, Tom WL, Chamlin SL, Feldman SR, Hanifin JM, Simpson EL, et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol. 2014;70(2):338-51. [Crossref]  [PubMed]  [PMC]
  22. Fujisawa T, Nagao M, Hiraguchi Y, Katsumata H, Nishimori H, Iguchi K, et al. Serum measurement of thymus andactivation-regulated chemokine/ccl17 in children with atopic dermatitis: elevated normal levels in infancy and age-specific analysis in atopic dermatitis. Pediatr Allergy Immunol. 2009;20(7):633-41. [Crossref]  [PubMed]
  23. Wollenberg A, Kinberger M, Arents B, Aszodi N, Barbarot S, Bieber T, et al. First Update Of The Living European Guideline (EuroGuiderm) on Atopic Eczema. J Eur Acad Dermatol Venereol. 2023;37(11):e1283-e7. [Crossref]
  24. Simpson EL, Chalmers JR, Hanifin JM, et al. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. J Allergy Clin Immunol. 2014;134(4):818-823. [Crossref]  [PubMed]  [PMC]
  25. Barnes PJ. Molecular Mechanisms And Cellular Effects Of Glucocorticosteroids. Immunol Allergy Clin North Am. 2005;25(3):451-68. [Crossref]  [PubMed]
  26. Eichenfield LF, Tom WL, Berger TG, Krol A, Paller AS, Schwarzenberger K, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(1):116-32. [Crossref]  [PubMed]  [PMC]
  27. Hoare C, Li Wan Po A, Williams H. Systematic review of treatments for atopic eczema. Health Technol Assess. 2000;4:1. [Crossref]  [PubMed]
  28. Aubert-Wastiaux H, Moret L, Le Rhun A, Fontenoy Am, Nguyen Jm, Leux C, et al. Topical corticosteroid phobia in atopic dermatitis: a study of its nature, origins and frequency. Br J Dermatol. 2011;165(4):808-14. [Crossref]  [PubMed]
  29. Drake LA, Dinehart SM, Farmer ER, et al. Guidelines of care for the use of topical glucocorticosteroids. American Academy of Dermatology. J Am Acad Dermatol. 1996;35(4):615-619. [Crossref]  [PubMed]
  30. Devillers AC, Oranje AP. Efficacy and safety of 'wet-wrap' dressings as an intervention treatment in children with severe and/or refractory atopic dermatitis: a critical review of the literature. Br J Dermatol. 2006;154:579. [Crossref]  [PubMed]
  31. Mayba JN, Gooderham MJ. Review of Atopic dermatitis and Topical Therapies. J cutan med Surg. 2017;21(3):227-36. [Crossref]  [PubMed]
  32. Simpson EL. Atopic dermatitis: a review of topical treatment options. Curr med res Opin. 2010;26:633-40. [Crossref]  [PubMed]
  33. Tennis P, Gelfand Jm, Rothman KJ. Evaluation of cancer risk related to atopic dermatitis and use of topical calcineurin inhibitors. Br J dermatol. 2011;165:465-73. [Crossref]  [PubMed]
  34. Tollefson MM, Bruckner AL; Section On Dermatology. Atopic dermatitis: skin-directed management. Pediatrics. 2014;134(6):e1735-e1744. [Crossref]  [PubMed]
  35. Alqahtani SM, Awaji BH, Mahdi AM, Althawab FH, Aljohani HM, Rayes RA, et al. Assessment and management of Atopic dermatitis in Primary care Set-tings: A Systematic review. Cureus. 2023;15(9):e44560. [Crossref]
  36. Papp K, Szepietowski JC, Kircik L, Toth D, Eichenfield LF, Leung DYM, et al. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: results from 2 phase 3, randomized, double-blind studies. J Am Acad dermatol. 2021;85(4):863-72. [Crossref]  [PubMed]
  37. Patrizi A, Raone B, Ravaioli GM. Management of atopic dermatitis: safety and efficacy of phototherapy. Clin Cosmet Investig Dermatol. 2015;8:511-20. [Crossref]  [PubMed]  [PMC]
  38. Salman A. Atopik dermatitte fototerapi. Su Küçük Ö, editör. Atopik dermatit. 1. baskı. Ankara: Türkiye Klinikleri; 2020. p.44-50. [Link]
  39. Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I [published correction appears in J Eur Acad Dermatol Venereol. 2019 Jul;33(7):1436. doi: 10.1111/jdv.15719.]. J Eur Acad Dermatol Venereol. 2018;32(5):657-682. [Link]
  40. Wollenberg A, Christen-Zäch S, Taieb A, Paul C, Thyssen JP, de BruinWeller M, et al. European Task force on Atopic dermatitis/EAdv Eczema Task force. ETfAd/EAdv Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. J Eur Acad derma-tol venereol. 2020;34(12):2717-44. [Crossref]  [PubMed]
  41. Wollenberg A, Barbarot S, Bieber T, Christen-Zaech S, Deleuran M, Finkwagner A, et al. consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. J Eur Acad Dermatol Venereol. 2018;32(6):850-78. [Link]
  42. Langan Sm, Irvine Ad, Weidinger S. Atopic dermatitis. lancet. 2020;396(10247):345-60. Erratum in: Lancet. 2020;396(10253):758. [Crossref]  [PubMed]
  43. Schram ME, Roekevisch E, Leeflang MM, Bos JD, Schmitt J, Spuls PI. A randomized trial of methotrexate versus azathioprine for severe atopic eczema. J Allergy Clin Immunol. 2011;128:353. [Crossref]  [PubMed]
  44. Phan K, Smith SD. mycophenolate mofetil and atopic dermatitis: systematic review and meta-analysis. J dermatolog Treat. 2020;31:810. [Crossref]  [PubMed]
  45. Wollenberg A, Kinberger M, Arents B, Aszodi N, Avila Valle G, Barbarot S, et al. European guideline (EuroGuiderm) on atopic eczema: part I - systemic therapy. J Eur Acad Dermatol Venereol. 2022;36(9):1409-31. [Crossref]  [PubMed]
  46. Wollenberg A, Blauvelt A, Guttman-Yassky E, Worm M, Lynde C, Lacour JP, et al; EczTrA 1 and EczTrA 2 study investigators. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (EczTrA 1 and EczTrA 2). Br J Dermatol. 2021;184(3):437-49. [Crossref]  [PubMed]  [PMC]
  47. Davis DMR, Drucker AM, Alikhan A, et al. Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies. J Am Acad Dermatol. 2024;90(2):e43-e56. [Crossref]  [PubMed]
  48. Simpson EL, Silverberg JI, Nosbaum A, Winthrop KL, Guttman-Yassky E, Hoffmeister KM, et al. Integrated safety analysis of abrocitinib for the treatment of moderate-to-severe atopic dermatitis from the phase II and phase III clinical trial program. Am J clin dermatol. 2021;22:693-707. [Crossref]  [PubMed]  [PMC]
  49. Kim RW, Lam M, Abuabara K, Simpson EL, Drucker AM. Targeted Systemic Therapies for Adults with Atopic dermatitis: Selecting from biologics and JAK Inhibitors. Am J Clin Dermatol. 2024;25(2):179-93. [Crossref]  [PubMed]
  50. Guttman-Yassky E, Thyssen JP, Silverberg JI, Papp KA, Paller AS, Weidinger S, et al. Safety of upadacitinib in moderate-to-severe atopic dermatitis: an integrated analysis of phase 3 studies. J Allergy clin Immunol.2023;151:172-81. [Crossref]  [PubMed]
  51. Bieber T, Katoh N, Simpson EL, De Bruin-Weller M, Thaçi D, Torrelo A, et al. Safety of baricitinib for the treatment of atopic dermatitis over a median of 1.6 years and up to 3.9 years of treatment: an updated integrated analysis of eight clinical trials. J Dermatol Treat. 2023;34:2161812. [Crossref]  [PubMed]